Acer Therapeutics to Virtually Present at Upcoming Investor Conferences
Acer Therapeutics Inc. (Nasdaq: ACER) announced a virtual corporate overview for September, 2020, at the LD Micro 500 Virtual Conference and H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Acer Therapeutics Inc. (Nasdaq: ACER) announced a virtual corporate overview for September, 2020, at the LD Micro 500 Virtual Conference and H.C. Wainwright 22nd Annual Global Investment Conference. The LD Micro event is scheduled for September 1, 2020, at 3 p.m. ET, while the H.C. Wainwright conference will occur on September 15, 2020, at 2:30 p.m. ET. Acer focuses on therapies for serious rare diseases, featuring a pipeline that includes options for COVID-19 and various genetic disorders. More details are available on their website.
Details
News Market Reaction – ACER
The recorded move for ACER in the trading session of this news was +4.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September, including the LD Micro 500 Virtual Conference and the H.C. Wainwright 22nd Annual Global Investment Conference.
Acer Conference Presentation Details:
| Conference: | LD Micro 500 Virtual Conference | |
| Date: | Tuesday, September 1, 2020 | |
| Time: | 3 p.m. Eastern Time | |
| Conference: | H.C. Wainwright 22nd Annual Global Investment Conference | |
| Date: | Tuesday, September 15, 2020 | |
| Time: | 2:30 p.m. Eastern Time | |
More information on Acer presentations can be found in the “Events and Presentations” section of Acer’s website at https://www.acertx.com/investor-relations/events-presentations/.
About Acer Therapeutics Inc.
Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant for the treatment of induced Vasomotor Symptoms (iVMS). Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. For more information, visit www.acertx.com.
Investor Contact:
Hans Vitzthum
LifeSci Advisors
Ph: 617-430-7578
hans@lifesciadvisors.com
Jim DeNike
Acer Therapeutics Inc.
Ph: 844-902-6100
jdenike@acertx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.